Crassula Launches Vascutan Plus, Irbesartan/Hydrochlorothiazide, in Honduras

Tegucigalpa, Honduras – Continuing its commitment to cardiovascular health, Crassula Pharmaceuticals is proud to announce the release of Vascutan Plus, a combination medication containing Irbesartan and Hydrochlorothiazide, in Honduras. This new addition enhances Crassula’s portfolio by offering a comprehensive treatment solution for hypertension.

Vascutan Plus combines Irbesartan, an angiotensin II receptor blocker (ARB), with Hydrochlorothiazide, a thiazide diuretic. This synergistic combination not only effectively lowers blood pressure by relaxing blood vessels but also helps eliminate excess salt and water from the body, further reducing blood pressure and the strain on the cardiovascular system.

“Crassula Pharmaceuticals remains at the forefront of innovation in healthcare with the launch of Vascutan Plus, aimed at providing a more effective hypertension management strategy,” stated Dr. Roopesh Gupta, CEO of Crassula Pharmaceuticals. “This advanced formula is designed to meet the diverse needs of patients dealing with high blood pressure, offering them a higher level of care and support.”

Vascutan Plus is now available throughout Honduras, signifying a key advancement in the management of hypertension and its associated risks. For more information on Vascutan Plus and other products from Crassula Pharmaceuticals, please visit www.crassulapharma.com or contact sales@crassulapharma.com.

About Crassula Pharmaceuticals

Specializing in high-quality healthcare products, Crassula Pharmaceuticals focuses on innovation, quality, and patient safety to enhance health and well-being both locally and globally. The company offers a wide range of therapeutic solutions designed to address the healthcare needs of the community.